The Medical Letter on Drugs and Therapeutics
Extended-Release Hydromorphone (Exalgo) for Pain
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Extended-Release Hydromorphone (Exalgo) for Pain
The FDA has approved the opioid agonist hydromorphone in a once-daily extended-release (ER) oral tablet formulation (Exalgo – Covidien) for the management of moderate to severe pain in opioid-tolerant patients requiring continuous, long-term...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Extended-Release Hydromorphone (Exalgo) for Pain
Article code: 1370b
 Electronic, downloadable article - $45

Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.